JAAHA is proud to present two papers in this issue that herald significant advances in the treatment of two common clinical diseases in dogs: namely, chronic valvular disease and pituitary-dependent hyperadrenocorticism. Reports on the efficacy of pimobendan (for certain cardiac diseases) and trilostane (for hyperadrenocorticism) have been filtering into the United States for several years.
In the cardiology section of this issue, readers will find a multicenter report from Europe on the use of pimobendan for congestive heart failure secondary to chronic atrioventricular valvular disease in dogs. Results of this study are very promising and fuel hope that pimobendan


